Companies › Daiichi Sankyo
22 active drug programs in 78 registered trials: 44 Phase 1, 20 Phase 3, 14 Phase 2; Oncology, Gastroenterology, Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ifinatamab deruxtecan (DS-7300a, I-DXd) Anti-B7H3 antibody-drug conjugate | B7H3, DLL3 | Phase 3 | Small Cell Lung Cancer; Esophageal Squamous Cell Carcinoma; Extensive-stage Small-cell Lung Cancer; Advanced Solid Tumor … | Dec 2026 |
| Datopotamab Deruxtecan Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 3 | Non-small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer; Urothelial Cancer; Advanced or Metastatic NSCLC … | Dec 2026 |
| Patritumab Deruxtecan Receptor tyrosine-protein kinase erbB-3 binding agent; DNA topoisomerase I inhibitor | ERBB3, TOP1 | Phase 3 | Nonsquamous Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer Metastatic; Advanced Solid Tumor; Non-Small Cell Lung Cancer (NSCLC) … | Dec 2026 |
| Pexidartinib Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor | CSF1R, FLT3, KIT | Phase 3 | Tenosynovial Giant Cell Tumor; Neurofibroma, Plexiform | Mar 2027 |
| Trastuzumab Deruxtecan Receptor protein-tyrosine kinase erbB-2 binding agent; DNA topoisomerase I inhibitor | ERBB2, TOP1 | Phase 3 | Breast Cancer; Gastric Cancer, Adenocarcinoma; Advanced Cancer; Gastric Cancer … | Mar 2027 |
| Quizartinib Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor | CSF1R, FLT3, KIT, PDGFRB, PDGFRA | Phase 3 | Leukemia; Acute Myeloid Leukemia; Hepatic Impairment; Acute Myeloid Leukemia, Adult … | May 2027 |
| raludotatug deruxtecan (R-DXd; DS-6000a) | – | Phase 2 | Solid Cancer; Advanced Solid Tumor; Renal Cell Carcinoma | Dec 2026 |
| DS-5141b (Renadirsen) Antisense oligonucleotide targeting dystrophin pre-mRNA | DYSTROPHIN | Phase 2 | Duchenne Muscular Dystrophy | Jan 2027 |
| DS-1001b Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 2 | WHO Grade II Glioma | Feb 2027 |
| Valemetostat Tosylate EZH1/2 dual inhibitor | EZH1, EZH2, KDM1A | Phase 2 | Relapsed/Refractory Peripheral T-Cell Lymphoma; Non-small Cell Lung Cancer; Advanced Solid Tumor; Lymphoma, B-Cell … | Mar 2028 |
| DS-1055a | – | Phase 1 | Solid Tumor | Jul 2027 |
| DS-3201b | – | Phase 1 | Lymphoma, Malignant | Dec 2027 |
| DS1025a | – | Phase 1 | Advanced Solid Tumor | Jan 2028 |
| Valemetostat (DS-3201b) Histone deacetylase inhibitor | HDAC (class I/II) | Phase 1 | Metastatic Castration-resistant Prostate Cancer; Aggressive Variant Prostate Carcinoma; Extensive-stage Small-cell Lung Cancer; Lymphoma … | Jan 2028 |
| DS9051b Unclear - code-named investigational drug | – | Phase 1 | Advanced or Metastatic Adrenocortical Carcinoma | Mar 2028 |
| DS-3939a | – | Phase 1 | Advanced Solid Tumor; Solid Tumor | Aug 2028 |
| DS3610a | – | Phase 1 | Solid Tumors | Sep 2028 |
| DS-2243a | – | Phase 1 | Solid Tumors | Nov 2028 |
| DS-1103a | – | Phase 1 | Advanced Solid Tumor; Solid Tumor | May 2029 |
| Olomorasib KRAS G12C inhibitor | KRAS | Phase 1 | Urothelial Cancer | Sep 2029 |
| DS5361b | – | Phase 1 | Advanced Solid Tumor | Mar 2030 |
| DS3790a | – | Phase 1 | Hematological Malignancies | Nov 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03529110 | Trastuzumab Deruxtecan | Phase 3 | Breast Cancer | Oncology | May 2021 |
| NCT03734029 | Trastuzumab Deruxtecan | Phase 3 | Breast Cancer | Oncology | Jan 2022 |
| NCT04842877 | Valemetostat Tosylate | Phase 2 | Lymphoma, B-Cell | Oncology | Dec 2024 |
| NCT04704934 | Trastuzumab Deruxtecan | Phase 3 | Gastric Cancer, Adenocarcinoma | Oncology | Aug 2026 |
| NCT06740799 | Quizartinib | Phase 1 | Hepatic Impairment | Gastroenterology | Oct 2026 |
| NCT05280470 | Ifinatamab deruxtecan (DS-7300a, I-DXd) | Phase 2 | Extensive-stage Small-cell Lung Cancer | Oncology | Dec 2026 |
| NCT04707248 | raludotatug deruxtecan (R-DXd; DS-6000a) | Phase 1 | Renal Cell Carcinoma | Oncology | Dec 2026 |
| NCT05338970 | Patritumab Deruxtecan | Phase 3 | Nonsquamous Non-small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT04526691 | Datopotamab Deruxtecan | Phase 1 | Advanced or Metastatic NSCLC | Oncology | Dec 2026 |
| NCT04388852 | Valemetostat (DS-3201b) | Phase 1 | Aggressive Variant Prostate Carcinoma | Oncology | Dec 2026 |
| NCT02390752 | Pexidartinib | Phase 1 | Neurofibroma, Plexiform | Oncology | Dec 2026 |
| NCT04619004 | Patritumab Deruxtecan | Phase 2 | Non-Small Cell Lung Cancer Metastatic | Oncology | Jan 2027 |
| NCT06807632 | Valemetostat (DS-3201b) | Phase 1 | Extensive-stage Small-cell Lung Cancer | Oncology | Jan 2027 |
| NCT04433234 | DS-5141b (Renadirsen) | Phase 2 | Duchenne Muscular Dystrophy | Neurology | Jan 2027 |
| NCT04656652 | Datopotamab Deruxtecan | Phase 3 | Non-small Cell Lung Cancer | Oncology | Feb 2027 |
| NCT04458272 | DS-1001b | Phase 2 | WHO Grade II Glioma | Oncology | Feb 2027 |
| NCT04042701 | Trastuzumab Deruxtecan | Phase 1 | Breast Cancer | Oncology | Mar 2027 |
| NCT04488822 | Pexidartinib | Phase 3 | Tenosynovial Giant Cell Tumor | Oncology | Mar 2027 |
| NCT04145622 | Ifinatamab deruxtecan (DS-7300a, I-DXd) | Phase 1 | Advanced Solid Tumor | Oncology | Apr 2027 |
| NCT03793478 | Quizartinib | Phase 1 | Acute Myeloid Leukemia | Oncology | May 2027 |
| NCT04419532 | DS-1055a | Phase 1 | Solid Tumor | Oncology | Jul 2027 |
| NCT06362252 | Ifinatamab deruxtecan (DS-7300a, I-DXd) | Phase 1 | Extensive Stage-small Cell Lung Cancer | Oncology | Jul 2027 |
| NCT03260491 | Patritumab Deruxtecan | Phase 1 | Non-Small Cell Lung Cancer (NSCLC) | Oncology | Jul 2027 |
| NCT06172478 | Patritumab Deruxtecan | Phase 2 | Advanced Solid Tumor | Oncology | Sep 2027 |
| NCT05683171 | Valemetostat (DS-3201b) | Phase 1 | Lymphoma | Oncology | Sep 2027 |
| NCT05950945 | Trastuzumab Deruxtecan | Phase 3 | Breast Cancer | Oncology | Oct 2027 |
| NCT04676477 | Patritumab Deruxtecan | Phase 1 | Non-Small Cell Lung Cancer (NSCLC) | Oncology | Dec 2027 |
| NCT04128748 | Quizartinib | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2027 |
| NCT04493138 | Quizartinib | Phase 1 | Chronic Myelomonocytic Leukemia | Oncology | Dec 2027 |
| NCT04047641 | Quizartinib | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2027 |
| NCT02732275 | DS-3201b | Phase 1 | Lymphoma, Malignant | Oncology | Dec 2027 |
| NCT03661307 | Quizartinib | Phase 1 | Acute Myeloid Leukemia | Oncology | Jan 2028 |
| NCT07681882 | DS1025a | Phase 1 | Advanced Solid Tumor | Oncology | Jan 2028 |
| NCT06203210 | Ifinatamab deruxtecan (DS-7300a, I-DXd) | Phase 3 | Small Cell Lung Cancer | Oncology | Jan 2028 |
| NCT06294548 | Valemetostat (DS-3201b) | Phase 1 | Hepatocellular Carcinoma | Oncology | Jan 2028 |
| NCT07244341 | Valemetostat (DS-3201b) | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Oncology | Jan 2028 |
| NCT06174987 | Trastuzumab Deruxtecan | Phase 3 | Advanced Cancer | Oncology | Feb 2028 |
| NCT06161025 | raludotatug deruxtecan (R-DXd; DS-6000a) | Phase 2 | Solid Cancer | Oncology | Feb 2028 |
| NCT07189403 | DS9051b | Phase 1 | Advanced or Metastatic Adrenocortical Carcinoma | Oncology | Mar 2028 |
| NCT06644768 | Valemetostat Tosylate | Phase 1 | Non-small Cell Lung Cancer | Oncology | Mar 2028 |
| NCT06644781 | Ifinatamab deruxtecan (DS-7300a, I-DXd) | Phase 3 | Esophageal Squamous Cell Carcinoma | Oncology | Jun 2028 |
| NCT06731478 | Trastuzumab Deruxtecan | Phase 3 | Gastric Cancer | Oncology | Jun 2028 |
| NCT06824168 | Quizartinib | Phase 2 | Acute Myeloid Leukemia | Oncology | Jun 2028 |
| NCT06262438 | Quizartinib | Phase 2 | Acute Myeloid Leukemia in Children | Oncology | Jun 2028 |
| NCT04622319 | Trastuzumab Deruxtecan | Phase 3 | HER2-Positive Primary Breast Cancer | Oncology | Jun 2028 |
| NCT06330064 | Ifinatamab deruxtecan (DS-7300a, I-DXd) | Phase 1 | Recurrent or Metastatic Solid Tumors | Oncology | Jul 2028 |
| NCT05875168 | DS-3939a | Phase 1 | Advanced Solid Tumor | Oncology | Aug 2028 |
| NCT07159126 | DS3610a | Phase 1 | Solid Tumors | Oncology | Sep 2028 |
| NCT06769490 | Quizartinib | Phase 1 | Acute Myeloid Leukemia | Oncology | Sep 2028 |
| NCT06819007 | Trastuzumab Deruxtecan | Phase 3 | Ovarian Cancer | Oncology | Nov 2028 |
| NCT06244485 | Trastuzumab Deruxtecan | Phase 1 | Advanced Solid Tumor | Oncology | Nov 2028 |
| NCT06244485 | Datopotamab Deruxtecan | Phase 1 | Advanced Solid Tumor | Oncology | Nov 2028 |
| NCT06244485 | Valemetostat Tosylate | Phase 1 | Advanced Solid Tumor | Oncology | Nov 2028 |
| NCT06644755 | DS-2243a | Phase 1 | Solid Tumors | Oncology | Nov 2028 |
| NCT07015697 | Trastuzumab Deruxtecan | Phase 1 | Recurrent or Metastatic Solid Tumors | Oncology | Dec 2028 |
| NCT05555732 | Datopotamab Deruxtecan | Phase 3 | Metastatic Non Small Cell Lung Cancer | Oncology | May 2029 |
| NCT05765851 | Trastuzumab Deruxtecan | Phase 1 | Advanced Solid Tumor | Oncology | May 2029 |
| NCT05765851 | DS-1103a | Phase 1 | Advanced Solid Tumor | Oncology | May 2029 |
| NCT07129993 | Datopotamab Deruxtecan | Phase 2 | Urothelial Cancer | Oncology | Jun 2029 |
| NCT04703192 | Valemetostat Tosylate | Phase 2 | Relapsed/Refractory Peripheral T-Cell Lymphoma | Oncology | Jun 2029 |
The 60 nearest readouts of 78 trials; the rest in the app.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.